Company profile
Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Pociredir | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04003974 | phase2 | completed | 2019-08-09 | 2021-01-28 | Fulcrum Therapeutics | Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) |
| NCT05397470 | phase3 | terminated | 2022-06-16 | 2024-11-19 | Fulcrum Therapeutics | Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) |
| NCT04264442 | phase2 | terminated | 2020-02-13 | 2024-11-07 | Fulcrum Therapeutics | Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE) |
| NCT04004000 | phase2 | terminated | 2019-08-23 | 2024-10-31 | Fulcrum Therapeutics | Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension |
| NCT04511819 | phase3 | terminated | 2020-08-28 | 2021-03-31 | Fulcrum Therapeutics | Losmapimod Safety and Efficacy in COVID-19 |
FDA applications (0)
No records yet.